Skip to content
2000
Volume 21, Issue 1
  • ISSN: 2772-4328
  • E-ISSN: 2772-4336

Abstract

Ketamine, a substance used for anesthesia and known for inducing dissociation, can lead to addiction and the development of severe withdrawal symptoms. Ketamine alters brain networks before affecting somesthetic sensation. Ketamine abuse was especially prevalent in East and Southeast Asia, and its popularity has continued to expand globally in recent decades. Ketamine is gaining popularity in the public and private sectors as a cheaper off-label depression treatment. Unfortunately, ketamine may cause side effects, such as heart and blood vessel instability, respiratory depression, liver injury, hallucinations, . The pain-relieving and mental effects of ketamine might induce reliance; thus, it should be used cautiously. This review highlights the neurobiological processes underpinnings of ketamine's addictive potential, withdrawal, and its effects on brain networks like the prefrontal cortex, hippocampus, and mesolimbic pathway, which play vital roles in decision-making, memory, and reward processing. In addition, the involvement of neurotransmitter systems, specifically glutamate and dopamine, in mediating the addictive properties of ketamine and the neuroadaptive changes that occurred during withdrawal are also discussed. It also explains that low-dose ketamine can alter the secretion of stress hormone cortisol and hypothalamic-pituitary-adrenal (HPA) axis dysregulation, possibly attributed to the current repurposing study of ketamine as a fast-acting antidepressant. Understanding these pathways is essential for developing effective ketamine addiction treatments, managing withdrawal symptoms, and possibly reversing brain changes for the betterment of human health and psychological well-being.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328362434250224105609
2025-03-03
2026-03-10

  • From This Site

    /content/journals/crcep/10.2174/0127724328362434250224105609
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DeWildeK.E. LevitchC.F. MurroughJ.W. MathewS.J. IosifescuD.V. The promise of ketamine for treatment-resistant depression: Current evidence and future directions.Ann. N. Y. Acad. Sci.201513451475810.1111/nyas.1264625649308
     [Google Scholar]
  2. PowersA.R.III GancsosM.G. FinnE.S. MorganP.T. CorlettP.R. Ketamine-induced hallucinations.Psychopathology201548637638510.1159/00043867526361209
     [Google Scholar]
  3. AlshammariT.K. The ketamine antidepressant story: New insights.Molecules20202523577710.3390/molecules2523577733297563
     [Google Scholar]
  4. Understanding current use of ketamine for emerging areas of therapeutic interestAvailable from: https://www.fda.gov/drugs/news-events-human-drugs/understanding-current-use-ketamine-emerging-areas-therapeutic-interest-06272024 2024
  5. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic.Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified 2020
  6. LiJ.H. KasinatherV. CheungY-W. ZhouW. NurhidayatA.W. JarlaisD. SchottenfeldR. To use or not to use: An update on licit and illicit ketamine use.Subst. Abuse Rehabil.20112112010.2147/SAR.S1545824474851
     [Google Scholar]
  7. BeertenS.G. MatheïC. AertgeertsB. Ketamine misuse: An update for primary care.Br. J. Gen. Pract.202373727878910.3399/bjgp23X73199736702586
     [Google Scholar]
  8. GandolfoP. SoeiroT. JouveÉ. RevolB. DaveluyA. BertinC. EidenC. GibajaV. ChaouachiL. Pérault-PochatM.C. ChevallierC. AquizérateA. Le BoisselierR. CartonL. Lapeyre-MestreM. FraugerÉ. LacroixC. MicallefJ. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the french addictovigilance network.Fundam. Clin. Pharmacol.202438597898710.1111/fcp.1299538372190
     [Google Scholar]
  9. PalamarJ.J. RutherfordC. KeyesK.M. Trends in ketamine use, exposures, and seizures in the United States up to 2019.Am. J. Public Health2021111112046204910.2105/AJPH.2021.30648634618543
     [Google Scholar]
  10. LalondeR. JoyalC.C. Effects of ketamine and L-glutamic acid diethyl ester on spatial and nonspatial learning tasks in rats.Pharmacol. Biochem. Behav.199344353954510.1016/0091‑3057(93)90164‑O8451257
     [Google Scholar]
  11. LiaoY. TangY. HaoW. Ketamine and international regulations.Am. J. Drug Alcohol Abuse201743549550410.1080/00952990.2016.127844928635347
     [Google Scholar]
  12. E/CN.7/2014/1 Annotated provisional agenda 2013.2013Available from: https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_57/_E-CN7-2014-01/E-CN7-2014-1_V1389004_E.pdf
  13. Further information provided by the People’s Republic of China on the proposed scheduling of ketamine 20152015Available from: https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_58/ECN72015_CRP5e_V1501482.pdf
  14. HardingL. Regulating ketamine use in psychiatry.J. Am. Acad. Psychiatry Law202351332032537657825
     [Google Scholar]
  15. Rosenbaum SB, Gupta V, Patel P, Palacios JL. Ketamine. In: StatPearls. Treasure Island, StatPearls Publishing: 2025.
  16. ZhangM.W. HarrisK.M. HoR.C. Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.BMC Med. Ethics2016171410.1186/s12910‑016‑0087‑326768892
     [Google Scholar]
  17. LiL. VlisidesP.E. Ketamine: 50 Years of modulating the mind.Front. Hum. Neurosci.20161061210.3389/fnhum.2016.0061227965560
     [Google Scholar]
  18. WangC. ZhengD. XuJ. LamW. YewD.T. Brain damages in ketamine addicts as revealed by magnetic resonance imaging.Front. Neuroanat.201372310.3389/fnana.2013.0002323882190
     [Google Scholar]
  19. ZanosP. MoaddelR. MorrisP.J. RiggsL.M. HighlandJ.N. GeorgiouP. PereiraE.F.R. AlbuquerqueE.X. ThomasC.J. ZarateC.A.Jr GouldT.D. Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms.Pharmacol. Rev.201870362166010.1124/pr.117.01519829945898
     [Google Scholar]
  20. ZorumskiC.F. IzumiY. MennerickS. Ketamine: NMDA receptors and beyond.J. Neurosci.20163644111581116410.1523/JNEUROSCI.1547‑16.201627807158
     [Google Scholar]
  21. LazarevicV. YangY. FlaisI. SvenningssonP. Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors.Mol. Psychiatry202126127425743510.1038/s41380‑021‑01246‑334376822
     [Google Scholar]
  22. HansenK.B. YiF. PerszykR.E. MennitiF.S. TraynelisS.F. NMDA receptors in the central nervous system.Methods Mol. Biol.2017167718010.1007/978‑1‑4939‑7321‑7_128986865
     [Google Scholar]
  23. ZhangC. LiZ. WuZ. ChenJ. WangZ. PengD. HongW. YuanC. WangZ. YuS. XuY. XuL. XiaoZ. FangY. A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression.Psychopharmacology2014231468569310.1007/s00213‑013‑3297‑024114429
     [Google Scholar]
  24. LvS. YaoK. ZhangY. ZhuS. NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research.Neuropharmacology202322510937810.1016/j.neuropharm.2022.10937836539011
     [Google Scholar]
  25. PribishA. WoodN. KalavaA. A review of nonanesthetic uses of ketamine.Anesthesiol. Res. Pract.2020202011510.1155/2020/579828532308676
     [Google Scholar]
  26. NiquetJ. BaldwinR. NormanK. SuchomelovaL. LumleyL. WasterlainC.G. Midazolam–ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.Epilepsia20165791406141510.1111/epi.1348027500978
     [Google Scholar]
  27. MionG. VillevieilleT. Ketamine pharmacology: An update (pharmacodynamics and molecular aspects, recent findings).CNS Neurosci. Ther.201319637038010.1111/cns.1209923575437
     [Google Scholar]
  28. SanacoraG. FryeM.A. McDonaldW. MathewS.J. TurnerM.S. SchatzbergA.F. SummergradP. NemeroffC.B. A consensus statement on the use of ketamine in the treatment of mood disorders.JAMA Psychiatry201774439940510.1001/jamapsychiatry.2017.008028249076
     [Google Scholar]
  29. CaffinoL. Di ChioM. GiannottiG. VenniroM. MuttiA. PadovaniL. CheungD. FumagalliG.F. YewD.T. FumagalliF. ChiamuleraC. The modulation of BDNF expression and signalling dissects the antidepressant from the reinforcing properties of ketamine: Effects of single infusion vs. chronic self-administration in rats.Pharmacol. Res.2016104223010.1016/j.phrs.2015.12.01426706783
     [Google Scholar]
  30. CaffinoL. MottarliniF. PivaA. RizziB. FumagalliF. ChiamuleraC. Temporal dynamics of BDNF signaling recruitment in the rat prefrontal cortex and hippocampus following a single infusion of a translational dose of ketamine.Neuropharmacology202424210976710.1016/j.neuropharm.2023.10976737858883
     [Google Scholar]
  31. WilkinsonS.T. ToprakM. TurnerM.S. LevineS.P. KatzR.B. SanacoraG. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders.Am. J. Psychiatry2017174769569610.1176/appi.ajp.2017.1702023928669202
     [Google Scholar]
  32. SamsudinN. BaileyR.P. RiesF. HashimS.N.A.B. FernandezJ.A. Assessing the impact of physical activity on reducing depressive symptoms: A rapid review.BMC Sports Sci. Med. Rehabil.202416110710.1186/s13102‑024‑00895‑538720395
     [Google Scholar]
  33. ThelenC. SensJ. MauchJ. PanditR. PitychoutisP.M. Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice.Behav. Brain Res.201631230531210.1016/j.bbr.2016.06.04127343934
     [Google Scholar]
  34. FranceschelliA. SensJ. HerchickS. ThelenC. PitychoutisP.M. Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and “depressed” mice exposed to chronic mild stress.Neuroscience2015290496010.1016/j.neuroscience.2015.01.00825595985
     [Google Scholar]
  35. LewisR.G. FlorioE. PunzoD. BorrelliE. The brain’s reward system in health and disease.Adv. Exp. Med. Biol.20211344576910.1007/978‑3‑030‑81147‑1_434773226
     [Google Scholar]
  36. ShiM. DingJ. LiL. BaiH. LiX. LanL. FanH. GaoL. Effects of ketamine on learning and memory in the hippocampus of rats through ERK, CREB, and Arc.Brain Sci.20201112710.3390/brainsci1101002733383707
     [Google Scholar]
  37. DattaM.S. ChenY. ChauhanS. ZhangJ. De La CruzE.D. GongC. TomerR. Whole-brain mapping reveals the divergent impact of ketamine on the dopamine system.Cell Rep.2023421211349110.1016/j.celrep.2023.11349138052211
     [Google Scholar]
  38. KotoulaV. StringarisA. MackesN. MazibukoN. HawkinsP.C.T. FureyM. CurranH.V. MehtaM.A. Ketamine modulates the neural correlates of reward processing in unmedicated patients in remission from depression.Biol. Psychiatry Cogn. Neurosci. Neuroimaging20227328529210.1016/j.bpsc.2021.05.00934126264
     [Google Scholar]
  39. CaffinoL. PivaA. MottarliniF. Di ChioM. GiannottiG. ChiamuleraC. FumagalliF. Ketamine self-administration elevates αCaMKII autophosphorylation in mood and reward-related brain regions in rats.Mol. Neurobiol.20185575453546110.1007/s12035‑017‑0772‑328948570
     [Google Scholar]
  40. LiuF. PattersonT.A. SadovovaN. ZhangX. LiuS. ZouX. HanigJ.P. PauleM.G. SlikkerW.Jr WangC. Ketamine-induced neuronal damage and altered N-methyl-D-aspartate receptor function in rat primary forebrain culture.Toxicol. Sci.2013131254855710.1093/toxsci/kfs29623065140
     [Google Scholar]
  41. VolkowN.D. WangG.J. FowlerJ.S. TomasiD. TelangF. BalerR. Addiction: Decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain’s control circuit.BioEssays201032974875510.1002/bies.20100004220730946
     [Google Scholar]
  42. VolkowN.D. MichaelidesM. BalerR. The neuroscience of drug reward and addiction.Physiol. Rev.20199942115214010.1152/physrev.00014.201831507244
     [Google Scholar]
  43. HuangM.C. ChenC.H. ChenL.Y. ChangH.M. ChenC.K. LinS.K. XuK. Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation.Psychopharmacology 20202371455310.1007/s00213‑019‑05342‑931377886
     [Google Scholar]
  44. VinsonG.P. BrennanC.H. Addiction and the adrenal cortex.Endocr. Connect.201323R1R1410.1530/EC‑13‑002823825159
     [Google Scholar]
  45. SinhaR. Stress and substance use disorders: Risk, relapse, and treatment outcomes.J. Clin. Invest.202413416e17288310.1172/JCI17288339145454
     [Google Scholar]
  46. SoraviaL.M. MoggiF. de QuervainD.J.F. Effects of cortisol administration on craving during in vivo exposure in patients with alcohol use disorder.Transl. Psychiatry2021111610.1038/s41398‑020‑01180‑y33414435
     [Google Scholar]
  47. LüscherC. MalenkaR.C. NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD).Cold Spring Harb. Perspect. Biol.201246a00571010.1101/cshperspect.a00571022510460
     [Google Scholar]
  48. JunH. HussainiS.M.Q. RigbyM.J. JangM.H. Functional role of adult hippocampal neurogenesis as a therapeutic strategy for mental disorders.Neural Plast.2012201212010.1155/2012/85428523346419
     [Google Scholar]
  49. MalbergJ.E. EischA.J. NestlerE.J. DumanR.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.J. Neurosci.200020249104911010.1523/JNEUROSCI.20‑24‑09104.200011124987
     [Google Scholar]
  50. RawatR. Tunc-OzcanE. McGuireT.L. PengC.Y. KesslerJ.A. Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice.Nat. Commun.2022131265010.1038/s41467‑022‑30386‑535551462
     [Google Scholar]
  51. LiN. LeeB. LiuR.J. BanasrM. DwyerJ.M. IwataM. LiX.Y. AghajanianG. DumanR.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.Science2010329599495996410.1126/science.119028720724638
     [Google Scholar]
  52. Moda-SavaR.N. MurdockM.H. ParekhP.K. FetchoR.N. HuangB.S. HuynhT.N. WitztumJ. ShaverD.C. RosenthalD.L. AlwayE.J. LopezK. MengY. NellissenL. GrosenickL. MilnerT.A. DeisserothK. BitoH. KasaiH. ListonC. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.Science20193646436eaat807810.1126/science.aat807830975859
     [Google Scholar]
  53. PhoumthipphavongV BarthasF HassettS KwanAC Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex.eNeuro201632ENEURO. 0133-15.2016
     [Google Scholar]
  54. WuH. SavaliaN.K. KwanA.C. Ketamine for a boost of neural plasticity: How, but also when?Biol. Psychiatry202189111030103210.1016/j.biopsych.2021.03.01434016377
     [Google Scholar]
  55. WuM. MinkowiczS. DumrongprechachanV. HamiltonP. KozorovitskiyY. Ketamine rapidly enhances glutamate-evoked dendritic spinogenesis in medial prefrontal cortex through dopaminergic mechanisms.Biol. Psychiatry202189111096110510.1016/j.biopsych.2020.12.02233637303
     [Google Scholar]
  56. DumanR.S. AghajanianG.K. SanacoraG. KrystalJ.H. Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants.Nat. Med.201622323824910.1038/nm.405026937618
     [Google Scholar]
  57. HedrickN.G. HarwardS.C. HallC.E. MurakoshiH. McNamaraJ.O. YasudaR. Rho GTPase complementation underlies BDNF-dependent homo- and heterosynaptic plasticity.Nature2016538762310410810.1038/nature1978427680697
     [Google Scholar]
  58. LiX. LiY. ZhaoJ. LiL. WangY. ZhangY. LiY. ChenY. LiuW. GaoL. Administration of ketamine causes autophagy and apoptosis in the rat fetal hippocampus and in PC12 cells.Front. Cell. Neurosci.2018122110.3389/fncel.2018.0002129456493
     [Google Scholar]
  59. DongC. AnandK.J.S. Developmental neurotoxicity of ketamine in pediatric clinical use.Toxicol. Lett.20132201536010.1016/j.toxlet.2013.03.03023566897
     [Google Scholar]
  60. YanJ. JiangH. Dual effects of ketamine: Neurotoxicity versus neuroprotection in anesthesia for the developing brain.J. Neurosurg. Anesthesiol.201426215516010.1097/ANA.000000000000002724275940
     [Google Scholar]
  61. SzczurowskaE. MarešP. NMDA and AMPA receptors: Development and status epilepticus.Physiol. Res.201362Suppl. 1S21S3810.33549/physiolres.93266224329701
     [Google Scholar]
  62. KavalaliE.T. MonteggiaL.M. Targeting homeostatic synaptic plasticity for treatment of mood disorders.Neuron2020106571572610.1016/j.neuron.2020.05.01532497508
     [Google Scholar]
  63. WeckmannK. DeeryM.J. HowardJ.A. FeretR. AsaraJ.M. DethloffF. FiliouM.D. LabermaierC. MaccarroneG. LilleyK.S. MuellerM. TurckC.W. Ketamine’s effects on the glutamatergic and GABAergic systems: A proteomics and metabolomics study in mice.Mol. Neuropsychiatry201951425131019917
     [Google Scholar]
  64. LeistnerC. MenkeA. Hypothalamic–pituitary–adrenal axis and stress.Handbook of clinical neurology.Elsevier20205564
     [Google Scholar]
  65. ChoudhuryD. AutryA.E. ToliasK.F. KrishnanV. Ketamine: Neuroprotective or neurotoxic?Front. Neurosci.20211567252610.3389/fnins.2021.67252634566558
     [Google Scholar]
  66. LiaoY. TangJ. CorlettP.R. WangX. YangM. ChenH. LiuT. ChenX. HaoW. FletcherP.C. Reduced dorsal prefrontal gray matter after chronic ketamine use.Biol. Psychiatry2011691424810.1016/j.biopsych.2010.08.03021035788
     [Google Scholar]
  67. LiaoY. TangJ. MaM. WuZ. YangM. WangX. LiuT. ChenX. FletcherP.C. HaoW. Frontal white matter abnormalities following chronic ketamine use: A diffusion tensor imaging study.Brain201013372115212210.1093/brain/awq13120519326
     [Google Scholar]
  68. LiQ. ShiL. LuG. YuH.L. YeungF.K. WongN.K. SunL. LiuK. YewD. PanF. WangD.F. ShamP.C. Chronic ketamine exposure causes white matter microstructural abnormalities in adolescent Cynomolgus monkeys.Front. Neurosci.20171128510.3389/fnins.2017.0028528579941
     [Google Scholar]
  69. Lopes-AguiarC. RuggieroR.N. RossignoliM.T. EstevesI.M. Peixoto-SantosJ.E. Romcy-PereiraR.N. LeiteJ.P. Long-term potentiation prevents ketamine-induced aberrant neurophysiological dynamics in the hippocampus-prefrontal cortex pathway in vivo.Sci. Rep.2020101716710.1038/s41598‑020‑63979‑532346044
     [Google Scholar]
  70. Khalili-MahaniN. MartiniC.H. OlofsenE. DahanA. NiestersM. Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion.Br. J. Anaesth.20151151687510.1093/bja/aev13525982133
     [Google Scholar]
  71. McNaughtonN. The role of the subiculum within the behavioural inhibition system.Behav. Brain Res.2006174223225010.1016/j.bbr.2006.05.03716887202
     [Google Scholar]
  72. ToffaninT. NifosìF. FolladorH. PassamaniA. ZontaF. FerriG. ScanariniM. AmistàP. PigatoG. ScaroniC. ManteroF. CarolloC. PeriniG.I. Volumetric MRI analysis of hippocampal subregions in Cushing’s disease: A model for glucocorticoid neural modulation.Eur. Psychiatry2011261646710.1016/j.eurpsy.2010.09.00321067899
     [Google Scholar]
  73. VythilingamM. LuckenbaughD.A. LamT. MorganC.A.III LipschitzD. CharneyD.S. BremnerJ.D. SouthwickS.M. Smaller head of the hippocampus in Gulf War-related posttraumatic stress disorder.Psychiatry Res. Neuroimaging20051392899910.1016/j.pscychresns.2005.04.00315967648
     [Google Scholar]
  74. NandamL.S. BrazelM. ZhouM. JhaveriD.J. Cortisol and major depressive disorder—Translating findings from humans to animal models and back.Front. Psychiatry20201097410.3389/fpsyt.2019.0097432038323
     [Google Scholar]
  75. AnderzhanovaE. HafnerK. GenewskyA.J. SolimanA. PöhlmannM.L. SchmidtM.V. BlumR. WotjakC.T. GassenN.C. The stress susceptibility factor FKBP51 controls S-ketamine-evoked release of mBDNF in the prefrontal cortex of mice.Neurobiol. Stress20201310023910.1016/j.ynstr.2020.10023933344695
     [Google Scholar]
  76. DeyamaS. BangE. WohlebE.S. LiX.Y. KatoT. GerhardD.M. DutheilS. DwyerJ.M. TaylorS.R. PicciottoM.R. DumanR.S. Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine.Am. J. Psychiatry2019176538840010.1176/appi.ajp.2018.1712136830606046
     [Google Scholar]
  77. DuttonM. CanA.T. BeaudequinD. JensenE. JonesM. GallayC.C. SchwennP.E. SchermanJ.K. YangC. ForsythG. LagopoulosJ. HermensD.F. Oral ketamine reduces the experience of stress in people with chronic suicidality.J. Affect. Disord.202230041041710.1016/j.jad.2022.01.01835016117
     [Google Scholar]
  78. DuttonM. CanA.T. LagopoulosJ. HermensD.F. Stress, mental disorder and ketamine as a novel, rapid acting treatment.Eur. Neuropsychopharmacol.202265152910.1016/j.euroneuro.2022.09.00636206584
     [Google Scholar]
  79. DumanR.S. SanacoraG. KrystalJ.H. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments.Neuron20191021759010.1016/j.neuron.2019.03.01330946828
     [Google Scholar]
  80. JansenK.L.R. Darracot-CankovicR. The nonmedical use of ketamine, part two: A review of problem use and dependence.J. Psychoactive Drugs200133215115810.1080/02791072.2001.1040048011476262
     [Google Scholar]
  81. CosciF. ChouinardG. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications.Psychother. Psychosom.202089528330610.1159/00050686832259826
     [Google Scholar]
  82. PalH.R. BerryN. KumarR. RayR. Ketamine dependence.Anaesth. Intensive Care200230338238410.1177/0310057X020300032312075653
     [Google Scholar]
  83. MorganC.J.A. MonaghanL. CurranH.V. Beyond the K-hole: A 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug.Addiction200499111450146110.1111/j.1360‑0443.2004.00879.x15500598
     [Google Scholar]
  84. MorganC.J.A. CurranH.V. Ketamine use: A review.Addiction20121071273810.1111/j.1360‑0443.2011.03576.x21777321
     [Google Scholar]
  85. KhoodoruthM.A.S. Estudillo-GuerraM.A. Pacheco-BarriosK. NyundoA. Chapa-KoloffonG. OuanesS. Glutamatergic aystem in sepression and its role in neuromodulatory techniques optimization.Front. Psychiatry20221388691810.3389/fpsyt.2022.88691835492692
     [Google Scholar]
  86. VinesL. SoteloD. JohnsonA. DennisE. ManzaP. VolkowN.D. WangG.J. Ketamine use disorder: Preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions.Intell. Med.202222616810.1016/j.imed.2022.03.00135783539
     [Google Scholar]
  87. HardaZ. MisiołekK. KlimczakM. ChrószczM. ParkitnaJ.R. Withdrawal from sub-chronic ketamine does not produce psychotic-like behavior in C57BL/6N mice.SSRN2021Available from: https://ssrn.com/abstract=3926148 10.2139/ssrn.3926148
     [Google Scholar]
  88. BeckK. HindleyG. BorganF. GinestetC. McCutcheonR. BruggerS. DriesenN. RanganathanM. D’SouzaD.C. TaylorM. KrystalJ.H. HowesO.D. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: A systematic review and meta-analysis.JAMA Netw. Open202035e20469310.1001/jamanetworkopen.2020.469332437573
     [Google Scholar]
  89. NeillJ.C. HarteM.K. HaddadP.M. LydallE.S. DwyerD.M. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans.Eur. Neuropsychopharmacol.201424582283510.1016/j.euroneuro.2013.09.01124287012
     [Google Scholar]
  90. de Carvalho CartágenesS. FernandesL.M.P. CarvalheiroT.C.V.S. de SousaT.M. GomesA.R.Q. MonteiroM.C. de Oliveira ParaenseR.S. Crespo-LópezM.E. LimaR.R. Fontes-JúniorE.A. PredigerR.D. MaiaC.S.F. “Special K” drug on adolescent rats: Oxidative damage and neurobehavioral impairments.Oxid. Med. Cell. Longev.20192019111010.1155/2019/545272731001375
     [Google Scholar]
  91. CartágenesS.C. da SilveiraC.C.S.M. PinheiroB.G. FernandesL.M.P. FariasS.V. KobayashiN.H.C. de SouzaP.H.F.S. PradoA.F. FerreiraM.K.M. LimaR.R. de OliveiraE.H.C. de LunaF.C.F. BurbanoR.M.R. Fontes-JúniorE.A. MaiaC.S.F. “K-Powder” exposure during adolescence elicits psychiatric disturbances associated with oxidative stress in female rats.Pharmaceuticals20221511137310.3390/ph1511137336355545
     [Google Scholar]
  92. StrousJ.F.M. WeelandC.J. van der DraaiF.A. DaamsJ.G. DenysD. LokA. SchoeversR.A. FigeeM. Brain changes associated with long-term ketamine abuse, A systematic review.Front. Neuroanat.20221679523110.3389/fnana.2022.79523135370568
     [Google Scholar]
  93. MukherjeeD. StankoskiD.M. TildenS.E. HuhnA.S. BixlerE.O. KongL. MeyerR.E. DenekeE. FreetC.S. BunceS.C. Reregulation of cortisol levels and sleep in patients with prescription opioid use disorder during long-term residential treatment.Drug Alcohol Depend.202122710893110.1016/j.drugalcdep.2021.10893134392049
     [Google Scholar]
  94. Maddox-RooperT.R. Sklioutouskaya-LopezK. SturgillT. FreschC. ClementsC.W.II LamichhaneR. EgletonR. DaviesT.H. Intake assessments of salivary cortisol, survey responses, and adverse childhood experiences are associated with recovery success in an abstinence-based treatment program for substance use disorders.Alcohol. Clin. Exp. Res.202246101865187410.1111/acer.1491336016476
     [Google Scholar]
  95. AbdulrahimD. Bowden-JonesO. Textbook of clinical management of club drugs and novel psychoactive substances: NEPTUNE clinical guidance.Cambridge University PressCambridge202210.1017/9781009182126
     [Google Scholar]
  96. ChenL.Y. ChenC.K. ChenC.H. ChangH.M. HuangM.C. XuK. Association of craving and depressive symptoms in ketamine-dependent patients undergoing withdrawal treatment.Am. J. Addict.2020291435010.1111/ajad.1297831691402
     [Google Scholar]
  97. LimD.K. Ketamine associated psychedelic effects and dependence.Singapore Med. J.2003441313412762561
     [Google Scholar]
  98. RoxasN. AhujaC. IsomJ. WilkinsonS.T. CapursoN. A potential case of acute ketamine withdrawal: Clinical implications for the treatment of refractory depression.Am. J. Psychiatry2021178758859110.1176/appi.ajp.2020.2010148034270337
     [Google Scholar]
  99. RobertsE. SandersonE. GuerriniI. The pharmacological management of ketamine use disorder: A systematic review.J. Addict. Med.202418557457910.1097/ADM.000000000000134038922637
     [Google Scholar]
  100. SchwenkE.S. ViscusiE.R. BuvanendranA. HurleyR.W. WasanA.D. NarouzeS. BhatiaA. DavisF.N. HootenW.M. CohenS.P. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American society of regional anesthesia and pain medicine, the American Academy of pain medicine, and the American society of anesthesiologists.Reg. Anesth. Pain Med.2018435110.1097/AAP.000000000000080629870457
     [Google Scholar]
  101. WinstockA.R. MitchesonL. GillattD.A. CottrellA.M. The prevalence and natural history of urinary symptoms among recreational ketamine users.BJU Int.2012110111762176610.1111/j.1464‑410X.2012.11028.x22416998
     [Google Scholar]
  102. Van AmsterdamJ. Van Den BrinkW. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study.Expert Opin. Drug Saf.2022211839410.1080/14740338.2021.194945434176409
     [Google Scholar]
/content/journals/crcep/10.2174/0127724328362434250224105609
Loading
Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review
Curr Rev Clin Exper Pharm 21, 1 (2026); https://doi.org/10.2174/0127724328362434250224105609
/content/journals/crcep/10.2174/0127724328362434250224105609
/content/journals/crcep/10.2174/0127724328362434250224105609
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): anesthesia; glutamate; glutamate receptor; Ketamine; neurobiology; phencyclidine (PCP)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test